Ongoing research in BRCA1 and BRCA2 has led to improved understanding and management of cancer risk. New treatments and preventive measures, such as PARP inhibitors, have been developed specifically for BRCA-mutated cancers, offering hope for better outcomes and quality of life for affected individuals.
